These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
186 related articles for article (PubMed ID: 18159030)
1. FDA approves new epoetin product: Roche unsure when it can market in United States. Thompson CA Am J Health Syst Pharm; 2008 Jan; 65(1):10. PubMed ID: 18159030 [No Abstract] [Full Text] [Related]
2. Rebates for anti-anemia drugs draw response from FDA, CMS. Sipkoff M Manag Care; 2007 Jun; 16(6):17-8. PubMed ID: 17682732 [No Abstract] [Full Text] [Related]
3. Drug distribution and expenditure: the issue of epoetin in Italy. La Vecchia C; Franceschi S; Apolone G Eur J Public Health; 2003 Dec; 13(4):367. PubMed ID: 14703326 [No Abstract] [Full Text] [Related]
5. FDA Approves First Oral Treatment for Kidney Disease-Induced Anemia. Harris E JAMA; 2023 Mar; 329(9):704. PubMed ID: 36790833 [No Abstract] [Full Text] [Related]
6. FDA approval of Omontys changes the ESA playing field. Neumann ME Nephrol News Issues; 2012 May; 26(6):17. PubMed ID: 22690453 [No Abstract] [Full Text] [Related]
7. EPO (epoetin) approval stirs cost concern in Congress. Wagner M Mod Healthc; 1989 Jun; 19(23):4. PubMed ID: 10293460 [No Abstract] [Full Text] [Related]
8. Peginesatide (Omontys) for anemia in chronic kidney failure. Med Lett Drugs Ther; 2012 Jun; 54(1392):45-6. PubMed ID: 22683926 [No Abstract] [Full Text] [Related]
9. The emerging role of biosimilar epoetins in nephrology in the United States. Fishbane S; Shah HH Am J Kidney Dis; 2015 Apr; 65(4):537-42. PubMed ID: 25582283 [TBL] [Abstract][Full Text] [Related]
10. Use of epoetin in chronic renal failure. Coyne DW JAMA; 2007 Apr; 297(15):1713-6. PubMed ID: 17440149 [No Abstract] [Full Text] [Related]
11. Regarding impact of epoetin alfa on clinical end points in patients with chronic renal failure: a meta-analysis. Tonelli M; Owen WF; Jindal K; Winkelmayer WC; Manns B Kidney Int; 2004 Oct; 66(4):1712; author reply 1712-3. PubMed ID: 15458473 [No Abstract] [Full Text] [Related]
12. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease. Besarab A; Salifu MO; Lunde NM; Bansal V; Fishbane S; Dougherty FC; Beyer U; Clin Ther; 2007 Apr; 29(4):626-39. PubMed ID: 17617286 [TBL] [Abstract][Full Text] [Related]
13. New ESA to be available for dialysis patients. Thompson CA Am J Health Syst Pharm; 2012 May; 69(9):731. PubMed ID: 22517015 [No Abstract] [Full Text] [Related]
14. Recombinant erythropoietin. Orphan product with a silver spoon. Coster JM Int J Technol Assess Health Care; 1992; 8(4):635-46. PubMed ID: 1464484 [TBL] [Abstract][Full Text] [Related]
15. Erythropoiesis-stimulating agents in kidney and cardiac disease. Fluck R Br J Hosp Med (Lond); 2006 Oct; 67(10):533-7. PubMed ID: 17069130 [No Abstract] [Full Text] [Related]
16. Use of Carnitor for Epogen resistant anemia. Simard JC ANNA J; 1999 Feb; 26(1):41-2. PubMed ID: 10222857 [TBL] [Abstract][Full Text] [Related]
17. New oversight put in place for physicians giving anemia drugs to patients with cancer. Mitka M JAMA; 2010 Apr; 303(14):1355-6. PubMed ID: 20388885 [No Abstract] [Full Text] [Related]
18. Use of methoxy polyethylene glycol-epoetin beta in stage 3, 4 or 5 non-dialysis chronic kidney disease. Padullés-Zamora N; Comas-Sugrañes D; Pineda-Yuste Mdel M; Jódar-Masanés R; Martínez-Castelao A Nefrologia; 2012; 32(2):221-7. PubMed ID: 22421952 [TBL] [Abstract][Full Text] [Related]